A Single-Arm, Single-Center Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Multiple Myeloma.
In: Vaccine Weekly, 2023-10-27, S. 42-42
serialPeriodical
Zugriff:
1) Corticosteroids: subjects who are receiving systemic steroid therapy within 2 weeks of blood collection scheduled for CAR-T at screening and require chronic systemic steroid therapy during treatment as judged by the investigator (except for inhaled or topical use); and subjects who are receiving systemic steroid therapy within 72 hours before cell reinfusion (except for inhaled or topical use); 2) Immunosuppressants: subjects who are receiving immunosuppressive agents within 2 weeks of blood collection scheduled for CAR-T at screening; 17. [Extracted from the article]
Copyright of Vaccine Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
A Single-Arm, Single-Center Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Multiple Myeloma.
|
---|---|
Zeitschrift: | Vaccine Weekly, 2023-10-27, S. 42-42 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1074-2921 (print) |
Schlagwort: |
|
Sonstiges: |
|